Royal Bank of Canada Has $43,000 Stock Position in Avanos Medical, Inc. $AVNS

Royal Bank of Canada cut its holdings in shares of Avanos Medical, Inc. (NYSE:AVNS) by 92.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,056 shares of the company’s stock after selling 39,824 shares during the period. Royal Bank of Canada’s holdings in Avanos Medical were worth $43,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in AVNS. EverSource Wealth Advisors LLC lifted its position in Avanos Medical by 132.6% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,496 shares of the company’s stock valued at $28,000 after acquiring an additional 1,423 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in Avanos Medical by 969.3% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,545 shares of the company’s stock worth $31,000 after purchasing an additional 2,307 shares in the last quarter. Wexford Capital LP purchased a new stake in shares of Avanos Medical in the third quarter worth approximately $70,000. Tower Research Capital LLC TRC raised its stake in shares of Avanos Medical by 433.0% in the second quarter. Tower Research Capital LLC TRC now owns 6,257 shares of the company’s stock worth $77,000 after purchasing an additional 5,083 shares during the last quarter. Finally, PNC Financial Services Group Inc. lifted its holdings in shares of Avanos Medical by 15.5% in the first quarter. PNC Financial Services Group Inc. now owns 6,317 shares of the company’s stock valued at $89,000 after purchasing an additional 846 shares in the last quarter. Institutional investors and hedge funds own 95.17% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on AVNS. Weiss Ratings reiterated a “sell (d-)” rating on shares of Avanos Medical in a report on Monday, July 20th. Zacks Research upgraded Avanos Medical from a “strong sell” rating to a “hold” rating in a research note on Friday, June 5th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Avanos Medical has an average rating of “Reduce”.

Avanos Medical Price Performance

Shares of NYSE:AVNS opened at $24.99 on Thursday. The company has a market capitalization of $1.17 billion, a P/E ratio of -15.52 and a beta of 1.57. The company’s 50-day moving average is $24.97 and its 200 day moving average is $21.66. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.40 and a current ratio of 2.48. Avanos Medical, Inc. has a fifty-two week low of $9.30 and a fifty-two week high of $25.49.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.